Cure My Disease

Don't miss your cure!

 Log in / Sign up

Allergy shots may unlock better asthma control by targeting hidden immune signals

NCT ID NCT07694947

Disease control Sponsor: Mansoura University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study looks at how allergy shots (subcutaneous allergen immunotherapy) affect immune markers in adults with allergic asthma. Researchers will measure changes in eosinophil cationic protein and sputum eosinophils over six months, along with asthma symptom scores. The goal is to understand whether these markers can predict who will benefit most from this treatment. Participants are adults with partially controlled allergic asthma who are already candidates for allergy shots.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
allergen immunotherapy extract (subcutaneous injection)
What this could lead to
If successful, this could help doctors predict which asthma patients will benefit most from allergy shots, leading to more personalized treatment.
What could go wrong
This is an early observational study, not a large trial. It may not prove that the treatment works for everyone, and some patients may not respond or may have allergic reactions to the shots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jan 2023

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age above 18 years and diagnosed of allergic asthma. Patients were clinical stabile and confirmed diagnosis supported by pulmonary function test. Exclusion Criteria: * pregnant * parasitic infestations * recent acute asthma exacerbation * current smoking * severe persistent asthma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic asthma

Contacts and locations

Locations

  • Mohamed AbdElmoniem

    Al Mansurah, 35516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.